<DOC>
	<DOCNO>NCT00480636</DOCNO>
	<brief_summary>To collect postmarketing data Fragmin safety efficacy treatment deep vein thrombosis without pulmonary embolism cancer patient .</brief_summary>
	<brief_title>Fragmin In The Treatment Of Acute Deep-Vein Thrombosis With Or Without Pulmonary Embolism In Cancer Patients</brief_title>
	<detailed_description>Method : consecutive patient sample . Patients ( ) include study consecutive manner fulfil inclusion criterion exclusion criterion present .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<criteria>Male female patient 18 70 year age . Cancer patient proven deepvein thrombosis without pulmonary embolism confirm combination clinical sign symptom , pulmonary hypertension echocardiogram , Xray examination lung eventually perfusion/ventilation scan lung . Bleeding Hypersensitivity FRAGMINÂ® lowmolecular weight heparin . Serum creatinine level &gt; 150 umol/l . Platelet count less 100 000 per cubic millimeter begin therapy . Patient oral anticoagulation therapy last 7 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>